Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001610717-26-000052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-17 | NMRA | BERNS PAUL L | See Remarks, Dir | S - Sale | $3.51 | -9,819 | 7.40M | -0.1% | -$34.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | S | D | 9,819 | $3.51 | 7,395,185 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $3.48 to $3.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |